210 related articles for article (PubMed ID: 29792121)
21. Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma?
Sella A; Hercbergs AH; Hanovich E; Kovel S
Chemotherapy; 2012; 58(3):200-5. PubMed ID: 22759787
[TBL] [Abstract][Full Text] [Related]
22. A Genetic Polymorphism in
Liu X; Swen JJ; Diekstra MHM; Boven E; Castellano D; Gelderblom H; Mathijssen RHJ; Vermeulen SH; Oosterwijk E; Junker K; Roessler M; Alexiusdottir K; Sverrisdottir A; Radu MT; Ambert V; Eisen T; Warren A; Rodríguez-Antona C; García-Donas J; Böhringer S; Koudijs KKM; Kiemeney LALM; Rini BI; Guchelaar HJ
Clin Cancer Res; 2018 May; 24(10):2350-2356. PubMed ID: 29490989
[No Abstract] [Full Text] [Related]
23. Hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy.
Kust D; Prpić M; Murgić J; Jazvić M; Jakšić B; Krilić D; Bolanča A; Kusić Z
Anticancer Res; 2014 Jun; 34(6):3177-84. PubMed ID: 24922691
[TBL] [Abstract][Full Text] [Related]
24. ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma.
Mizuno T; Terada T; Kamba T; Fukudo M; Katsura T; Nakamura E; Ogawa O; Inui K
Ann Oncol; 2010 Jun; 21(6):1382-1383. PubMed ID: 20348146
[No Abstract] [Full Text] [Related]
25. Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients.
Buda-Nowak A; Kucharz J; Dumnicka P; Kuzniewski M; Herman RM; Zygulska AL; Kusnierz-Cabala B
Med Oncol; 2017 Apr; 34(4):68. PubMed ID: 28343336
[TBL] [Abstract][Full Text] [Related]
26. Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics.
Mizuno T; Fukudo M; Terada T; Kamba T; Nakamura E; Ogawa O; Inui K; Katsura T
Drug Metab Pharmacokinet; 2012; 27(6):631-9. PubMed ID: 22673043
[TBL] [Abstract][Full Text] [Related]
27. Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma.
Chu YH; Li H; Tan HS; Koh V; Lai J; Phyo WM; Choudhury Y; Kanesvaran R; Chau NM; Toh CK; Ng QS; Tan PH; Chowbay B; Tan MH
PLoS One; 2015; 10(8):e0134102. PubMed ID: 26244574
[TBL] [Abstract][Full Text] [Related]
28. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Rini BI; Tamaskar I; Shaheen P; Salas R; Garcia J; Wood L; Reddy S; Dreicer R; Bukowski RM
J Natl Cancer Inst; 2007 Jan; 99(1):81-3. PubMed ID: 17202116
[TBL] [Abstract][Full Text] [Related]
29. Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?
Sabatier R; Eymard JC; Walz J; Deville JL; Narbonne H; Boher JM; Salem N; Marcy M; Brunelle S; Viens P; Bladou F; Gravis G
Ann Oncol; 2012 Mar; 23(3):714-721. PubMed ID: 21653681
[TBL] [Abstract][Full Text] [Related]
30. Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function.
Kitajima K; Takahashi S; Maeda T; Yoshikawa T; Ohno Y; Fujii M; Miyake H; Fujisawa M; Sugimura K
Eur J Radiol; 2012 Sep; 81(9):2060-5. PubMed ID: 21724350
[TBL] [Abstract][Full Text] [Related]
31. Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.
Diekstra MH; Fritsch A; Kanefendt F; Swen JJ; Moes D; Sörgel F; Kinzig M; Stelzer C; Schindele D; Gauler T; Hauser S; Houtsma D; Roessler M; Moritz B; Mross K; Bergmann L; Oosterwijk E; Kiemeney LA; Guchelaar HJ; Jaehde U
CPT Pharmacometrics Syst Pharmacol; 2017 Sep; 6(9):604-613. PubMed ID: 28571114
[TBL] [Abstract][Full Text] [Related]
32. Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib.
Beuselinck B; Jean-Baptiste J; Schöffski P; Couchy G; Meiller C; Rolland F; Allory Y; Joniau S; Verkarre V; Elaidi R; Lerut E; Roskams T; Patard JJ; Oudard S; Méjean A; Lambrechts D; Zucman-Rossi J
BJU Int; 2016 Dec; 118(6):890-901. PubMed ID: 27417418
[TBL] [Abstract][Full Text] [Related]
33. Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia.
Cheng F; Cui Z; Li Q; Chen S; Li W; Zhang Y
Int Immunopharmacol; 2024 May; 133():112090. PubMed ID: 38640718
[TBL] [Abstract][Full Text] [Related]
34. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Miyake H; Imai S; Harada K; Fujisawa M
Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
[TBL] [Abstract][Full Text] [Related]
35. Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.
Bianconi M; Faloppi L; Loretelli C; Zizzi A; Giampieri R; Bittoni A; Andrikou K; Del Prete M; Burattini L; Montironi R; Scartozzi M; Cascinu S
Oncotarget; 2016 Jun; 7(25):37599-37607. PubMed ID: 27175586
[TBL] [Abstract][Full Text] [Related]
36. Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients.
Teo YL; Wee HL; Chue XP; Chau NM; Tan MH; Kanesvaran R; Wee HL; Ho HK; Chan A
Pharmacogenomics J; 2016 Feb; 16(1):47-53. PubMed ID: 25778465
[TBL] [Abstract][Full Text] [Related]
37. Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma.
Igarashi R; Inoue T; Fujiyama N; Tsuchiya N; Numakura K; Kagaya H; Saito M; Narita S; Satoh S; Niioka T; Miura M; Habuchi T
Med Oncol; 2018 Mar; 35(4):51. PubMed ID: 29524031
[TBL] [Abstract][Full Text] [Related]
38. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
[TBL] [Abstract][Full Text] [Related]
39. Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma.
Sato S; Muraishi K; Tani J; Sasaki Y; Tokubuchi I; Tajiri Y; Yamada K; Suekane S; Miyajima J; Matsuoka K; Hiromatsu Y
Endocr J; 2010; 57(10):873-80. PubMed ID: 20733268
[TBL] [Abstract][Full Text] [Related]
40. Thyroid profile during the alternative Sunitinib dosing 2/1 schedule in metastatic renal cell carcinoma.
Rizza L; Sbardella E; Gianfrilli D; Lauretta R; Tenuta M; Del Bene G; Longo F; Faggiano A; Lenzi A; Giannetta E; Pozza C
Endocrine; 2020 Mar; 67(3):597-604. PubMed ID: 31679139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
